Sam Altman and other leading AI executives are pushing Congress to create mandatory screening rules for synthetic DNA purchases, warning that artificial intelligence systems could soon help bad actors create biological weapons. The OpenAI CEO and co-founder joined Anthropic's Dario Amodei and other tech leaders in signing an open letter last month that called for lawmakers to establish clear guidelines for monitoring online orders of synthetic DNA.

Why Are AI Leaders Concerned About Synthetic DNA?

The concern centers on a straightforward but alarming possibility: as AI systems become more capable, they could lower the barriers that have historically prevented malicious actors from obtaining biological weapons. The signatories warned that "AI systems are improving rapidly, and alongside incredible benefits to science and medicine, there is a real possibility that the knowledge barriers which have historically prevented bad actors from obtaining biological weapons will meaningfully erode".

This warning reflects a broader recognition within the tech industry that the same AI tools driving medical breakthroughs and scientific discovery could be misused. The Trump administration's AI Action Plan, released in July 2025, similarly flagged that AI could be weaponized to "create new pathways for malicious actors to synthesize harmful pathogens and other biomolecules".

What Is the White House Doing to Address These Risks?

The Trump administration responded to these concerns by releasing new guidance on July 29, 2026, that establishes federal oversight of high-risk life sciences research. The 12-page policy prohibits federal funding for dangerous gain-of-function research, which the guidance defines as research that "enhances a property or properties of a biological agent in ways that make it more dangerous".

Rather than banning AI use in biological research outright, the administration created a monitoring framework. The White House Office of Science and Technology Policy will convene an interagency group to oversee advancements at the intersection of biological sciences and artificial intelligence, including computational life sciences research.

How Will the New Policy Balance Innovation With Safety?

The policy attempts to distinguish between research that poses genuine risks and purely computational work that should remain unrestricted. According to the guidance, the new rules apply only when a proposal includes plans to create or modify a biological agent that meets the definition of dangerous gain-of-function research and results from computational research. Purely computational work, such as developing software models or designing novel biological agents through simulation alone, is not prohibited unless it involves entities of concern.

"The policy is based on three principles: that there are categories of research too risky to pursue, such as dangerous gain-of-function research and international research lacking appropriate oversight; that the entirety of the biomedical research enterprise must assess and monitor risks; and that researchers, institutions and funders will be held accountable for evaluating and reporting on high-risk research," said Jay Bhattacharya, Director of the National Institutes of Health.

Jay Bhattacharya, Director of the National Institutes of Health

The policy fulfills an earlier executive order signed by President Trump in May 2025 on biological research security and safety. Federal officials have indicated the new guidance aims to limit support for pathogen research that carries substantial risk of harming Americans.

Steps to Understanding the New Oversight Framework

• Interagency Monitoring: The White House Office of Science and Technology Policy will establish a coordinated group to track developments where AI and biological sciences intersect, ensuring no single agency misses emerging risks.
• Funding Restrictions: Federal agencies will no longer provide financial support for domestic dangerous gain-of-function research or certain international studies lacking proper oversight mechanisms.
• Accountability Measures: Researchers, institutions, and funding organizations must actively assess, monitor, and report on high-risk research activities to maintain compliance with the new framework.
• Computational Research Carve-Out: Purely software-based research and modeling work remain permitted unless they involve entities deemed a security concern, preserving space for legitimate scientific innovation.

The timing of these policy moves reflects growing urgency within both the tech industry and government. Altman's involvement in the open letter signals that major AI companies recognize their responsibility in preventing misuse of their technologies. The White House's Genesis Mission, launched in November 2025 to harness AI and emerging technologies for U.S. innovation, includes biotechnology as a priority area, making the balance between advancement and safety increasingly critical.

The policy release comes amid ongoing debate about pandemic origins, with some lawmakers continuing to investigate whether COVID-19 resulted from a laboratory leak in Wuhan, China. This context underscores why policymakers are treating biological research oversight as a matter of national security.